{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:10:29Z","timestamp":1760267429616,"version":"3.44.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1053\/j.seminhematol.2016.04.015","type":"journal-article","created":{"date-parts":[[2016,4,9]],"date-time":"2016-04-09T20:17:24Z","timestamp":1460233044000},"page":"S51-S53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"S1","title":["Current treatments and developments in pemphigoid diseases as paradigm diseases for autoantibody-driven, organ-specific autoimmune diseases"],"prefix":"10.1053","volume":"53","author":[{"given":"Christian D.","family":"Sadik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Detlef","family":"Zillikens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9863","key":"10.1053\/j.seminhematol.2016.04.015_bib1","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"issue":"3","key":"10.1053\/j.seminhematol.2016.04.015_bib2","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.det.2011.03.010","article-title":"Clinical features and practical diagnosis of bullous pemphigoid","volume":"29","author":"Schmidt","year":"2011","journal-title":"Dermatol Clin"},{"issue":"2","key":"10.1053\/j.seminhematol.2016.04.015_bib3","first-page":"81","article-title":"[Immune phenotyping of mononuclear infiltrate in bullous pemphigoid]","volume":"43","author":"Ambach","year":"1992","journal-title":"Hautarzt Zeitschr Dermatol Venerol verwandte Gebiete"},{"issue":"12","key":"10.1053\/j.seminhematol.2016.04.015_bib4","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/j.1600-0625.2011.01378.x","article-title":"Lesional Th17 cells and regulatory T cells in bullous pemphigoid","volume":"20","author":"Arakawa","year":"2011","journal-title":"Exp Dermatol"},{"issue":"1","key":"10.1053\/j.seminhematol.2016.04.015_bib5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/path.2157","article-title":"NADPH oxidase is required for neutrophil-dependent autoantibody-induced tissue damage","volume":"212","author":"Chiriac","year":"2007","journal-title":"J Pathol"},{"issue":"5","key":"10.1053\/j.seminhematol.2016.04.015_bib6","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/path.1674","article-title":"Granulocyte-derived elastase and gelatinase B are required for dermal-epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid","volume":"204","author":"Shimanovich","year":"2004","journal-title":"J Pathol"},{"issue":"4","key":"10.1053\/j.seminhematol.2016.04.015_bib7","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1046\/j.1523-1747.2002.01720.x","article-title":"Autoantibodies to bullous pemphigoid antigen 180 induce dermal-epidermal separation in cryosections of human skin","volume":"118","author":"Sitaru","year":"2002","journal-title":"J Invest Dermatol"},{"issue":"8","key":"10.1053\/j.seminhematol.2016.04.015_bib8","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1038\/jid.2012.35","article-title":"Incidence and mortality of bullous pemphigoid in France","volume":"132","author":"Joly","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1053\/j.seminhematol.2016.04.015_bib9","doi-asserted-by":"crossref","first-page":"a180","DOI":"10.1136\/bmj.a180","article-title":"Bullous pemphigoid and pemphigus vulgaris\u2014incidence and mortality in the UK: population based cohort study","volume":"337","author":"Langan","year":"2008","journal-title":"BMJ"},{"issue":"2","key":"10.1053\/j.seminhematol.2016.04.015_bib10","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1365-2133.2011.10413.x","article-title":"Mortality of bullous pemphigoid in Switzerland: a prospective study","volume":"165","author":"Cortes","year":"2011","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1053\/j.seminhematol.2016.04.015_bib11","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa011592","article-title":"A comparison of oral and topical corticosteroids in patients with bullous pemphigoid","volume":"346","author":"Joly","year":"2002","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2016.04.015_bib12","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1161\/STROKEAHA.110.596361","article-title":"Increased risk of stroke in patients with bullous pemphigoid: a population-based follow-up study","volume":"42","author":"Yang","year":"2011","journal-title":"Stroke"},{"issue":"6","key":"10.1053\/j.seminhematol.2016.04.015_bib13","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/bjd.12806","article-title":"Mortality of bullous pemphigoid in Singapore: risk factors and causes of death in 359 patients seen at the National Skin Centre","volume":"170","author":"Cai","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1053\/j.seminhematol.2016.04.015_bib14","first-page":"6","article-title":"Increased risk of venous thromboembolism in patients with bullous pemphigoid. The INVENTEP (INcidence of VENous ThromboEmbolism in bullous Pemphigoid) study","volume":"114","author":"Cugno","year":"2015","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1053\/j.seminhematol.2016.04.015_bib15","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/archderm.134.4.465","article-title":"High risk of death in elderly patients with extensive bullous pemphigoid","volume":"134","author":"Roujeau","year":"1998","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1053\/j.seminhematol.2016.04.015_bib16","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/bjd.13717","article-title":"Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology","volume":"17","author":"Feliciani","year":"2015","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1053\/j.seminhematol.2016.04.015_bib17","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2133.2006.07646.x","article-title":"Rituximab in autoimmune bullous diseases: mixed responses and adverse effects","volume":"156","author":"Schmidt","year":"2007","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1053\/j.seminhematol.2016.04.015_bib18","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1525-1470.2008.00751.x","article-title":"Severe bullous pemphigoid in an infant\u2014successful treatment with rituximab","volume":"25","author":"Schulze","year":"2008","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"10.1053\/j.seminhematol.2016.04.015_bib19","first-page":"431","article-title":"[Efficacy of rituximab in a case of refractory bullous pemphigoid]","volume":"136","author":"Reguiai","year":"2009","journal-title":"Ann Dermatol Venereol"},{"issue":"6","key":"10.1053\/j.seminhematol.2016.04.015_bib20","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1067\/mjd.2001.116337","article-title":"Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment","volume":"45","author":"Ahmed","year":"2001","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1053\/j.seminhematol.2016.04.015_bib21","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2165\/00128071-200405030-00003","article-title":"Efficacy and safety of intravenous immunoglobulin for immune-mediated skin disease: current view","volume":"5","author":"Ruetter","year":"2004","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"10.1053\/j.seminhematol.2016.04.015_bib22","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.jaad.2014.06.014","article-title":"Treatment of bullous pemphigoid with adjuvant immunoadsorption: a case series","volume":"71","author":"Kasperkiewicz","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1053\/j.seminhematol.2016.04.015_bib23","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1744-9987.2012.01075.x","article-title":"Immunoadsorption in dermatology","volume":"16","author":"Meyersburg","year":"2012","journal-title":"Ther Apher Dial"},{"issue":"8","key":"10.1053\/j.seminhematol.2016.04.015_bib24","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.molmed.2013.06.003","article-title":"Emerging treatments for pemphigoid diseases","volume":"19","author":"Ludwig","year":"2013","journal-title":"Trends Mol Med"},{"issue":"4","key":"10.1053\/j.seminhematol.2016.04.015_bib25","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1172\/JCI200521386","article-title":"Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen","volume":"115","author":"Sitaru","year":"2005","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1053\/j.seminhematol.2016.04.015_bib26","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.4049\/jimmunol.1100596","article-title":"Repetitive immunization breaks tolerance to type XVII collagen and leads to bullous pemphigoid in mice","volume":"187","author":"Hirose","year":"2011","journal-title":"J Immunol"},{"issue":"8","key":"10.1053\/j.seminhematol.2016.04.015_bib27","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1016\/j.ajpath.2014.05.007","article-title":"Fcgamma receptors III and IV mediate tissue destruction in a novel adult mouse model of bullous pemphigoid","volume":"184","author":"Schulze","year":"2014","journal-title":"Am J Pathol"},{"issue":"5","key":"10.1053\/j.seminhematol.2016.04.015_bib28","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.4049\/jimmunol.177.5.3461","article-title":"Induction of complement-fixing autoantibodies against type VII collagen results in subepidermal blistering in mice","volume":"177","author":"Sitaru","year":"2006","journal-title":"J Immunol"},{"issue":"18","key":"10.1053\/j.seminhematol.2016.04.015_bib29","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.2174\/1381612821666150316122502","article-title":"Animal models to investigate pathomechanisms and evaluate novel treatments for autoimmune bullous dermatoses","volume":"21","author":"Iwata","year":"2015","journal-title":"Curr Pharmaceut Design"},{"issue":"1-2","key":"10.1053\/j.seminhematol.2016.04.015_bib30","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s12016-007-0027-6","article-title":"Autoimmunity to type VII collagen: epidermolysis bullosa acquisita","volume":"33","author":"Woodley","year":"2007","journal-title":"Clin Rev Allergy Immunol"},{"issue":"8","key":"10.1053\/j.seminhematol.2016.04.015_bib31","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.4049\/jimmunol.1402688","article-title":"Caspase-1-independent IL-1 release mediates blister formation in autoantibody-induced tissue injury through modulation of endothelial adhesion molecules","volume":"194","author":"Sadeghi","year":"2015","journal-title":"J Immunol"},{"issue":"2","key":"10.1053\/j.seminhematol.2016.04.015_bib32","doi-asserted-by":"crossref","first-page":"559","DOI":"10.4049\/jimmunol.1301556","article-title":"GM-CSF modulates autoantibody production and skin blistering in experimental epidermolysis bullosa acquisita","volume":"192","author":"Samavedam","year":"2014","journal-title":"J Immunol"},{"key":"10.1053\/j.seminhematol.2016.04.015_bib33","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jaut.2012.08.002","article-title":"Recombinant IL-6 treatment protects mice from organ specific autoimmune disease by IL-6 classical signalling-dependent IL-1ra induction","volume":"40","author":"Samavedam","year":"2013","journal-title":"J Autoimmun"},{"issue":"4","key":"10.1053\/j.seminhematol.2016.04.015_bib34","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jaut.2012.04.002","article-title":"Enzymatic autoantibody glycan hydrolysis alleviates autoimmunity against type VII collagen","volume":"39","author":"Hirose","year":"2012","journal-title":"J Autoimmun"},{"issue":"1","key":"10.1053\/j.seminhematol.2016.04.015_bib35","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/path.4023","article-title":"Genetic identification and functional validation of FcgammaRIV as key molecule in autoantibody-induced tissue injury","volume":"228","author":"Kasperkiewicz","year":"2012","journal-title":"J Pathol"},{"issue":"9","key":"10.1053\/j.seminhematol.2016.04.015_bib36","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/nm.2862","article-title":"Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcgammaRIIB and dectin-1","volume":"18","author":"Karsten","year":"2012","journal-title":"Nat Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2016.04.015_bib37","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/JID.2015.361","article-title":"Dimethylfumarate Impairs Neutrophil Functions","volume":"136","author":"Muller","year":"2015","journal-title":"J Invest Dermatol"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196316300270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196316300270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:24:55Z","timestamp":1758522295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196316300270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":37,"alternative-id":["S0037196316300270"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2016.04.015","relation":{},"ISSN":["0037-1963"],"issn-type":[{"type":"print","value":"0037-1963"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current treatments and developments in pemphigoid diseases as paradigm diseases for autoantibody-driven, organ-specific autoimmune diseases","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2016.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}